Release Date: 10/11/16 10:05 Summary: Managing Directors Address to shareholders Price Sensitive: No Download Document 803.02KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%